EGFR and colorectal cancer: Although the response to anti-EGFR mAbs observed in some patients has confirmed that EGFR activation is oncogenic, as predicted by cellular and animal models, the molecular mechanisms underlying EGFR activation in colorectal cancer remain obscure and are probably heterogeneous.